Sherin Shaaban1, Leigh Ramos-Platt2, Floyd H Gilles3, Wai-Man Chan4, Caroline Andrews5, Umberto De Girolami6, Joseph Demer7, Elizabeth C Engle8. 1. Department of Neurology, Boston Children's Hospital, Boston, Massachusetts2F. B. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts3Program in Genomics, Boston Children's Hospital, Boston, Massachusetts4Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts5Dubai Harvard Foundation for Medical Research, Boston, Massachusetts. 2. Division of Pediatric Neurology, Children's Hospital Los Angeles, Los Angeles, California. 3. Division of Pathology (Neuropathology), Children's Hospital Los Angeles, Los Angeles, California. 4. Department of Neurology, Boston Children's Hospital, Boston, Massachusetts3Program in Genomics, Boston Children's Hospital, Boston, Massachusetts8Howard Hughes Medical Institute, Chevy Chase, Maryland. 5. Department of Neurology, Boston Children's Hospital, Boston, Massachusetts2F. B. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts8Howard Hughes Medical Institute, Chevy Chase, Maryland. 6. Department of Pathology, Boston Children's Hospital, Boston, Massachusetts10Department of Pathology, Harvard Medical School, Boston, Massachusetts11Division of Neuropathology, Brigham and Women's Hospital, Boston, Massachusetts. 7. Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles13Department of Neurology, Jules Stein Eye Institute, University of California, Los Angeles14Department of Bioengineering, Jules Stein Eye Institute, University of California, Los Angeles15Neuroscience Interdepartmental Programs, Jules Stein Eye Institute, University of California, Los Angeles. 8. Department of Neurology, Boston Children's Hospital, Boston, Massachusetts2F. B. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts3Program in Genomics, Boston Children's Hospital, Boston, Massachusetts4Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts8Howard Hughes Medical Institute, Chevy Chase, Maryland16Department of Medicine (Genetics), Boston Children's Hospital, Boston, Massachusetts17Department of Ophthalmology, Boston Children's Hospital, Boston, Massachusetts18Department of Neurology, Harvard Medical School, Boston, Massachusetts19Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts20Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Abstract
IMPORTANCE: Total ophthalmoplegia can result from ryanodine receptor 1 (RYR1) mutations without overt associated skeletal myopathy. Patients carrying RYR1 mutations are at high risk of developing malignant hyperthermia. Ophthalmologists should be familiar with these important clinical associations. OBJECTIVE: To determine the genetic cause of congenital ptosis, ophthalmoplegia, facial paralysis, and mild hypotonia segregating in 2 pedigrees diagnosed with atypical Moebius syndrome or congenital fibrosis of the extraocular muscles. DESIGN, SETTING, AND PARTICIPANTS: Clinical data including medical and family histories were collected at research laboratories at Boston Children's Hospital and Jules Stein Eye Institute (Engle and Demer labs) for affected and unaffected family members from 2 pedigrees in which patients presented with total ophthalmoplegia, facial weakness, and myopathy. INTERVENTION: Homozygosity mapping and whole-exome sequencing were conducted to identify causative mutations in affected family members. Histories, physical examinations, and clinical data were reviewed. MAIN OUTCOME AND MEASURE: Mutations in RYR1. RESULTS: Missense mutations resulting in 2 homozygous RYR1 amino acid substitutions (E989G and R3772W) and 2 compound heterozygous RYR1 substitutions (H283R and R3772W) were identified in a consanguineous and a nonconsanguineous pedigree, respectively. Orbital magnetic resonance imaging revealed marked hypoplasia of extraocular muscles and intraorbital cranial nerves. Skeletal muscle biopsy specimens revealed nonspecific myopathic changes. Clinically, the patients' ophthalmoplegia and facial weakness were far more significant than their hypotonia and limb weakness and were accompanied by an unrecognized susceptibility to malignant hyperthermia. CONCLUSIONS AND RELEVANCE: Affected children presenting with severe congenital ophthalmoplegia and facial weakness in the setting of only mild skeletal myopathy harbored recessive mutations in RYR1, encoding the ryanodine receptor 1, and were susceptible to malignant hyperthermia. While ophthalmoplegia occurs rarely in RYR1-related myopathies, these children were atypical because they lacked significant weakness, respiratory insufficiency, or scoliosis. RYR1-associated myopathies should be included in the differential diagnosis of congenital ophthalmoplegia and facial weakness, even without clinical skeletal myopathy. These patients should also be considered susceptible to malignant hyperthermia, a life-threatening anesthetic complication avoidable if anticipated presurgically.
IMPORTANCE: Total ophthalmoplegia can result from ryanodine receptor 1 (RYR1) mutations without overt associated skeletal myopathy. Patients carrying RYR1 mutations are at high risk of developing malignant hyperthermia. Ophthalmologists should be familiar with these important clinical associations. OBJECTIVE: To determine the genetic cause of congenital ptosis, ophthalmoplegia, facial paralysis, and mild hypotonia segregating in 2 pedigrees diagnosed with atypical Moebius syndrome or congenital fibrosis of the extraocular muscles. DESIGN, SETTING, AND PARTICIPANTS: Clinical data including medical and family histories were collected at research laboratories at Boston Children's Hospital and Jules Stein Eye Institute (Engle and Demer labs) for affected and unaffected family members from 2 pedigrees in which patients presented with total ophthalmoplegia, facial weakness, and myopathy. INTERVENTION: Homozygosity mapping and whole-exome sequencing were conducted to identify causative mutations in affected family members. Histories, physical examinations, and clinical data were reviewed. MAIN OUTCOME AND MEASURE: Mutations in RYR1. RESULTS: Missense mutations resulting in 2 homozygous RYR1 amino acid substitutions (E989G and R3772W) and 2 compound heterozygous RYR1 substitutions (H283R and R3772W) were identified in a consanguineous and a nonconsanguineous pedigree, respectively. Orbital magnetic resonance imaging revealed marked hypoplasia of extraocular muscles and intraorbital cranial nerves. Skeletal muscle biopsy specimens revealed nonspecific myopathic changes. Clinically, the patients' ophthalmoplegia and facial weakness were far more significant than their hypotonia and limb weakness and were accompanied by an unrecognized susceptibility to malignant hyperthermia. CONCLUSIONS AND RELEVANCE: Affected children presenting with severe congenital ophthalmoplegia and facial weakness in the setting of only mild skeletal myopathy harbored recessive mutations in RYR1, encoding the ryanodine receptor 1, and were susceptible to malignant hyperthermia. While ophthalmoplegia occurs rarely in RYR1-related myopathies, these children were atypical because they lacked significant weakness, respiratory insufficiency, or scoliosis. RYR1-associated myopathies should be included in the differential diagnosis of congenital ophthalmoplegia and facial weakness, even without clinical skeletal myopathy. These patients should also be considered susceptible to malignant hyperthermia, a life-threatening anesthetic complication avoidable if anticipated presurgically.
Authors: S T Sherry; M H Ward; M Kholodov; J Baker; L Phan; E M Smigielski; K Sirotkin Journal: Nucleic Acids Res Date: 2001-01-01 Impact factor: 16.971
Authors: R L Robinson; N Monnier; W Wolz; M Jung; A Reis; G Nuernberg; J L Curran; K Monsieurs; P Stieglitz; L Heytens; R Fricker; C van Broeckhoven; T Deufel; P M Hopkins; J Lunardi; C R Mueller Journal: Hum Mol Genet Date: 1997-06 Impact factor: 6.150
Authors: P J Lynch; J Tong; M Lehane; A Mallet; L Giblin; J J Heffron; P Vaughan; G Zafra; D H MacLennan; T V McCarthy Journal: Proc Natl Acad Sci U S A Date: 1999-03-30 Impact factor: 11.205
Authors: Natasha Kraeva; Sheila Riazi; Julian Loke; Wanda Frodis; Mary Lou Crossan; Kevin Nolan; Alexander Kraev; David H Maclennan Journal: Can J Anaesth Date: 2011-03-31 Impact factor: 5.063
Authors: H Jungbluth; H Zhou; L Hartley; B Halliger-Keller; S Messina; C Longman; M Brockington; S A Robb; V Straub; T Voit; M Swash; A Ferreiro; G Bydder; C A Sewry; C Müller; F Muntoni Journal: Neurology Date: 2005-12-27 Impact factor: 9.910
Authors: J A Bevilacqua; N Monnier; M Bitoun; B Eymard; A Ferreiro; S Monges; F Lubieniecki; A L Taratuto; A Laquerrière; K G Claeys; I Marty; M Fardeau; P Guicheney; J Lunardi; N B Romero Journal: Neuropathol Appl Neurobiol Date: 2011-04 Impact factor: 8.090
Authors: Andreas Gnirke; Alexandre Melnikov; Jared Maguire; Peter Rogov; Emily M LeProust; William Brockman; Timothy Fennell; Georgia Giannoukos; Sheila Fisher; Carsten Russ; Stacey Gabriel; David B Jaffe; Eric S Lander; Chad Nusbaum Journal: Nat Biotechnol Date: 2009-02-01 Impact factor: 54.908
Authors: Sheila Riazi; Natalia Kraeva; Sheila M Muldoon; James Dowling; Clara Ho; Maria-Alexandra Petre; Jerome Parness; Robert T Dirksen; Henry Rosenberg Journal: Can J Anaesth Date: 2014-09-05 Impact factor: 5.063